10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the a...

Full description

Bibliographic Details
Main Author: I. V. Kolyadina
Format: Article
Language:Russian
Published: ABV-press 2021-10-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/864